{"id":18199,"date":"2026-08-12T10:44:49","date_gmt":"2026-08-12T10:44:49","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&p=18199"},"modified":"2026-08-12T10:44:50","modified_gmt":"2026-08-12T10:44:50","slug":"early-solid-form-assessment-supports-candidate-selection-for-storm-therapeutics-dhx9-inhibitor-program","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/early-solid-form-assessment-supports-candidate-selection-for-storm-therapeutics-dhx9-inhibitor-program\/","title":{"rendered":"Early Solid Form Assessment Supports Candidate Selection for STORM Therapeutics’ DHX9 Inhibitor Program"},"content":{"rendered":"\n

How did Sygnature Discovery\u2019s Form & Formulation team help de-risk two lead candidates using only 200 mg of material?<\/strong><\/h2>\n\n\n\n
\"Workflow
API: Active Pharmaceutical Ingredient<\/figcaption><\/figure>\n\n\n\n

Customer Background<\/strong><\/h2>\n\n\n\n

STORM Therapeutics is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting RNA-modification pathways. As part of its DHX9 inhibitor discovery program, STORM collaborated with Sygnature Discovery\u2019s integrated drug discovery teams to rapidly progress novel chemical matter from lead identification<\/strong> to pre-candidate nomination in just 18 months<\/strong><\/a> <\/strong>(Figure 1).<\/p>\n\n\n\n

\"Timeline
Figure 1. <\/strong>Timeline that got STORM from Lead to Candidate Phase
You can read more about Sygnature Discovery\u2019s partnership with storm here.<\/strong><\/a>
<\/figcaption><\/figure>\n\n\n\n

As the program entered late lead optimization, two highly differentiated DHX9 inhibitor candidates remained under consideration. Both compounds demonstrated compelling pharmacology, DMPK properties, and developability characteristics, making candidate selection challenging.<\/p>\n\n\n\n

At this critical point,<\/p>\n\n\n\n

Understanding the solid-state behavior of each molecule became an important factor in reducing downstream development risk.<\/strong><\/p>\n\n\n\n

The Challenge<\/strong><\/h2>\n\n\n\n

Although both compounds were routinely isolated as crystalline solids, little was known about their solid-form landscapes.<\/p>\n\n\n\n

The project team needed to answer two key questions:<\/p>\n\n\n\n